Almirall

Almirall Days Payable Outstanding

The Days Payable Outstanding (DPO) of Almirall (ALM.MC) as of Nov 15, 2026 is 108.62. In the previous year, Days Payable Outstanding (DPO) was 312.24 — a change of -65.21% (lower).

Days Payable Outstanding

108.62

YoY

-65.21%

Last updated:

Days Payable Outstanding (DPO) of Almirall is 2025 108.62 . Days Payable Outstanding (DPO) of Almirall was 2024 312.24 . It decreases by -65.21% lower compared to the previous year.

The Almirall Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
428.82 EUR
Jan 1, 2019
421.92 EUR
Jan 1, 2020
341.32 EUR
Jan 1, 2021
378.23 EUR
Jan 1, 2022
368.64 EUR
Jan 1, 2023
208.55 EUR
Jan 1, 2024
312.24 EUR
Jan 1, 2025
108.62 EUR
The Almirall Days Payable Outstanding history
YEARDays Payable OutstandingYoY
108.62-65.21%
312.24+49.72%
208.55-43.43%
368.64-2.54%
378.23+10.81%
341.32-19.10%
421.92-1.61%
428.82+44.56%
296.64-44.24%
532.04-2.45%
545.38+17.42%
464.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Almirall Stock analysis

What does Almirall do? The company Almirall SA is a globally operating pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943 by Antonio Gallardo Ballart, the company has since become one of the leading companies in the field of dermatology and respiratory diseases. Almirall specializes in the development, manufacturing, and marketing of medications used in the treatment of skin conditions such as psoriasis or eczema, as well as respiratory diseases such as asthma or chronic bronchitis. The company focuses on close collaboration with doctors and patients to achieve the best possible therapeutic success. Almirall's business model is based on collaboration with other pharmaceutical companies to develop and bring innovative medications to the market. The company has its own research and development departments and also conducts clinical trials to test the safety and efficacy of new medications. Additionally, Almirall operates its own network of distribution and marketing partners to distribute its products worldwide. Almirall is organized into three divisions: dermatology, respiratory diseases, and other therapeutic areas. The dermatology division includes the development and marketing of medications for the treatment of skin conditions such as psoriasis and eczema. Some examples of products in this division are Skilarence, a medication for the treatment of moderate to severe psoriasis, and Kigozi, a topical medication for the treatment of atopic dermatitis. The respiratory diseases division includes the development and marketing of medications for the treatment of asthma and chronic bronchitis. The company offers a wide range of medications in this area that can be used in inhalation or tablet therapy. Some of the well-known products in this division are Alvesco, an inhaled corticosteroid for the treatment of asthma, and Ebastel, a medication for the treatment of allergic reactions. In other therapeutic areas, Almirall is involved in the development of new medications for the treatment of diseases such as ulcerative colitis or schizophrenia. For example, the company has developed Sativex, a cannabis-based medication for the treatment of multiple sclerosis-related spasticity, which is already approved in several countries. Throughout its history, Almirall has received numerous awards and recognition, including for the development of innovative medications and its work in the field of sustainability and corporate social responsibility. Through its commitment to research and development and collaboration with other pharmaceutical companies, Almirall will continue to play an important role in the global pharmaceutical industry market. Almirall is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Almirall stock

Days Payable Outstanding (DPO) of Almirall is 108.62 in 2025.

Days Payable Outstanding (DPO) of Almirall changed from 312.24 to 108.62, representing a -65.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Almirall since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Almirall with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Almirall

All Key Metrics — Almirall